Risk of culture-confirmed borrelial persistence in patients treated for erythema migrans and possible mechanisms of resistance

International Journal of Medical Microbiology

Volumn 296, Issue SUPPL. 1, 2006, Pages 233-241

  Hunfeld, Klaus Peter ^a,b   Ružić Sabljić, Eva ^c   Norris, Douglas E ^b   Kraiczy, Peter ^a   Strle, Franc ^d  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Borrelia burgdorferi; Erythema migrans; In vitro susceptibility; Molecular typing; Treatment resistance

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; ISONIAZID; MACROLIDE; PENICILLIN G; PYRAZINAMIDE; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; BORRELIA INFECTION; CLINICAL FEATURE; DRUG TREATMENT FAILURE; ERYTHEMA CHRONICUM MIGRANS; FOLLOW UP; HUMAN; LYME DISEASE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERSISTENT INFECTION; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SHORT SURVEY; SKIN BIOPSY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 33646358470     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2006.01.028     Document Type: Short Survey

References (60)

1. Aberer E., Kersten A., Klade H., Poitschek C., and Jurecka W. Heterogeneity of Borrelia burgdorferi in the skin. Am. J. Dermatopathol. 18 (1996) 571-579
2. Arnez M., Radsel-Medvescek A., Pleterski-Rigler D., Ružić-Sabljić E., and Strle F. Comparison of cefuroxime, axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien. Klin. Wochenschr. 111 (1999) 916-922
3. Berglund J., Eitrem R., Ornstein K., Lindberg A., Rignér A., Elmrud H., Carlsson M., Runehagen A., Svanborg K., and Norrby R. An epidemiological study of Lyme disease in southern Sweden. N. Engl. J. Med. 333 (1995) 1319-1324
4. Bockenstedt L.K., Mao J., Hodzic E., Barthold S.W., and Fish D. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J. Infect. Dis. 186 (2002) 1430-1437
5. Breier F., Khanakah G., Stanek G., Kunz G., Aberer E., Schmidt B., and Tappeiner G. Isolation and polymerase chain reaction typing of Borrelia afzelii from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus. Br. J. Dermatol. 144 (2001) 387-392
6. Brorson O., and Brorson S.H. Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection 25 (1997) 240-246
7. Brouqui P., Badiaga S., and Raoult D. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Antimicrob. Agents Chemother. 40 (1996) 1552-1554
8. CDC. Lyme disease - United States, 2000. Morb. Mortal. Wkly. Rep. 51 (2002) 29-31
9. Comstock L.E., and Thomas D.D. Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect. Immun. 57 (1989) 1626-1628
10. Gasser R., Reisinger E., Eber B., Pokan R., Seinost G., Bergloff J., Horwarth R., Sedaj B., and Klein W. Cases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta-lactamase inhibition. Microb. Drug Resist. 1 (1995) 341-344
11. Gerber M.A., Shapiro E.D., Burke G.S., Parcells V.J., and Bell G.L. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N. Engl. J. Med. 335 (1996) 1270-1274
12. Hansen K., Hovmark A., Lebech A.M., Lebech K., Olsson I., Halkier-Sorensen L., Olsson E., and Åsbrink E. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm. Venereol. 72 (1992) 297-300
13. Hassler D., Zöller L., Haude M., Hufnagel H.D., Heinrich F., and Sonntag H.G. Cefotaxime versus penicillin in the late stage of Lyme disease - a prospective, randomized therapeutic study. Infection 18 (1990) 16-20
14. Hunfeld K.-P., Kraiczy P., Wichelhaus T.A., Schäfer V., and Brade V. A new colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur. J. Clin. Microbiol. Infect. Dis. 19 (2000) 27-32
15. Hunfeld K.-P., Kraiczy P., Kekoukh E., Schäfer V., and Brade V. Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents - possible implications for new therapeutic approaches to Lyme disease. Int. J. Med. Microbiol. 291 Suppl. 33 (2002) 125-137
16. Hunfeld K.-P., Rödel R., and Wichelhaus T.A. In vitro activity of eight oral cephalosporins against Borrelia burgdorferi. Int. J. Antimicrob. Agents 23 (2003) 313-318
17. Hunfeld K.-P., Wichelhaus T.A., Rodel R., Acker G., Brade V., and Kraiczy P. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 48 (2004) 344-347
18. Hunfeld K.-P., Ružić-Sabljić E., Norris D.E., Kraiczy P., and Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob. Agents Chemother. 49 (2005) 1294-1301
19. Klempner M.S., Hu L.T., Evans J., Schmid C.H., Johnson G.M., Trevino R.P., Norton D., Levy L., Wall D., McCall J., Kosinski M., and Weinstein A. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345 (2001) 85-92
20. Kraiczy P., Weigand J., Wichelhaus T.A., Heisig P., Backes H., Schäfer V., Acker G., Brade V., and Hunfeld K.-P. In vitro activity of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 45 (2001) 2486-2494
21. Logar M., Lotric-Furlan S., Maraspin V., Cimperman J., Jurca T., Ružić-Sabljić E., and Strle F. Has the presence or absence of Borrelia burgdorferi sensu lato as detected by skin culture any influence on the course of erythema migrans?. Wien. Klin. Wochenschr. 111 (1999) 945-950
22. Lomholt H., Lebech A.M., Hansen K., Brandrup F., and Halkier-Sorensen L. Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. Acta Derm. Venereol. 80 (2000) 362-366
23. Luft B.J., Dattwyler R.J., Johnson R.C., Luger S.W., Bosler E.M., Rahn D.W., Masters E.J., Grunwaldt E., and Gadgil S.D. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann. Intern. Med. 124 (1996) 785-791
24. Ma Y., Sturrock A., and Weis J.J. Intracellular localisation of Borrelia burgdorferi within endothelial cells. Infect. Immun. 59 (1991) 671-678
25. Maes E., Lecomte P., and Ray N. A cost-of-illness study of Lyme disease in the United States. Clin. Ther. 20 (1998) 993-1008
26. Manning P.G. Fulminant refractory Lyme disease. Iowa Med. 79 (1989) 277-280
27. Misonne M.E., van Impe G., and Hoet P. Genetic heterogeneity of Borrelia burgdorferi in I. ricinus ticks collected in Belgium. J. Clin. Microbiol. 36 (1998) 3352-3354
28. Nadelman R.B., Nowakowski J., Forseter G., Bittker S., Cooper D., Goldberg N., McKenna D., and Wormser G.P. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: a report of a prospective study. Am. J. Med. 94 (1993) 583-588
29. Nowakowski J., McKenna D., Nadelman R.B., Cooper D., Bittker S., Holmgren D., Pavia C., Johnson R.C., and Wormser G.P. Failure of treatment with cephalexin for Lyme disease. Arch. Fam. Med. 9 (2000) 563-567
30. O'Connell S., Granström M., Gray J.S., and Stanek G. Epidemiology of European Lyme borreliosis. Zentralbl. Bakteriol. 287 (1998) 229-240
31. Oksi J., Marjamaki M., Nikoskelainen J., and Viljanen M.K. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann. Med. 31 (1999) 225-232
32. Pachner A.R., Basta J., Delaney E., and Hulinska D. Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy. Am. J. Trop. Med. Hyg. 52 (1995) 128-133
33. Panconesi E., Zuccati G., and Cantini A. Treatment of syphilis: a short critical review. Sex. Transm. Dis. 8 (1981) 321-325
34. Pfister H.W., Preac-Mursic V., Wilske B., Schielke E., Sorgel F., and Einhäupl K.M. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J. Infect. Dis. 163 (1991) 311-318
35. Postic D., Assous M.V., Grimont P.A.D., and Baranton G. Diversity of Borrelia burgdorferi sensu lato evidenced by restriction fragment length polymorphism of rrf(5S)-rrl(23S) intergenic spacer amplicons. Int. J. Syst. Bacteriol. 44 (1994) 743-752
36. Preac-Mursic V., Wilske B., and Schierz G. European Borrelia burgdorferi isolated from humans and ticks: culture conditions and antibiotic susceptibility. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 263 (1986) 112-118
37. Preac-Mursic V., Weber K., Pfister H.W., Wilske B., Gross B., Baumann A., and Prokop J. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17 (1989) 355-359
38. Preac-Mursic V., Marget W., Busch U., Pleterski-Riegler D., and Hagel S. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. Infection 24 (1996) 9-16
39. Rijpkema S.G., Tazelaar D.J., Molkenboer M.J., Noordhoek G.T., Plantinga G., Schouls L.M., and Schellekens J.F. Detection of Borrelia afzelii, Borrelia burgdorferi sensu stricto, Borrelia garinii and group VS116 by PCR in skin biopsies of patients with erythema migrans and acrodermatitis chronica atrophicans. Clin. Microbiol. Infect. 3 (1997) 109-116
40. Ružić-Sabljić E., Arnez M., Lotric-Furlan S., Maraspin V., Cimperman J., and Strle F. Genotypic and phenotypic characterisation of Borrelia burgdorferi sensu lato strains isolated from human blood. J. Med. Microbiol. 50 (2001) 896-901
41. Ružić-Sabljić E., Podreka T., Maraspin V., and Strle F. Susceptibility of Borrelia afzelii strains to antimicrobial agents. Int. J. Antimicrob. Agents 25 (2005) 474-778
42. Ružić-Sabljić E., Arnez M., Logar M., Maraspin V., Lotric-Furlan S., Cimperman J., and Strle F. Comparison of Borrelia burgdorferi sensu lato strains isolated from specimens obtained simultaneously from two different sites of an individual patient. J. Clin. Microbiol. 43 (2005) 2194-2200
43. Schwartz I., Wormser G.P., Schwartz J.J., Cooper D., Weissensee P., Gazumyan A., Zimmermann E., Goldberg N.S., Bittker S., Campbell G.L., and Pavia C.S. Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J. Clin. Microbiol. 30 (1992) 3082-3088
44. Sicklinger M., Wienecke R., and Neubert U. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J. Clin. Microbiol. 41 (2003) 1791-1793
45. Smith R.P., Schoen R.T., Rahn D.W., Sikand V.K., Nowakowski J., Parenti D.L., Holman M.S., Persing D.H., and Steere A.C. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann. Intern. Med. 136 (2002) 421-428
46. Stanek G., O'Connell S., Cimmino M., Aberer E., Kristoferitsch W., Granström M., Guy E., and Gray J. European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien. Klin. Wochenschr. 108 (1996) 741-747
47. Steere A.C. Lyme disease. N. Engl. J. Med. 345 (2001) 115-125
48. Straubinger R.K., Summers B.A., Chang Y.F., and Appel M.J.G. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J. Clin. Microbiol. 35 (1997) 111-116
49. Strle F., Preac-Mursic V., Cimperman J., Ružić E., Maraspin V., and Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 21 (1993) 83-88
50. Strle F., Maraspin V., Lotric-Furlan S., Ružić-Sabljić E., and Cimperman J. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection 24 (1996) 64-68
51. Strle F., Nelson J.A., Ružić-Sabljić E., Cimperman J., Maraspin V., Lotric-Furlan S., Cheng Y., Picken M.M., Trenholme G.M., and Picken R.N. European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin. Infect. Dis. 23 (1996) 61-65
52. Terekhova D., Sartakova M.L., Wormser G.P., Schwartz I., and Cabello F.C. Erythromycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 46 (2002) 3637-3640
53. Thanassi W.T., and Schoen R.T. The Lyme disease vaccine: conception, development, and implementation. Ann. Intern. Med. 132 (2000) 661-668
54. Van Dam A.P., Kuiper H., Vos K., Widjojokusumo A., Spanjaard L., de Jongh B.M., Ramselaar A.C.P., Kramer M.D., and Dankert J. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17 (1993) 708-717
55. Viljanen M.K., Oksi J., Salomaa P., Skurnik M., Peltonen R., and Kalimo H. Cultivation of Borrelia burgdorferi from the blood and a subcutaneous lesion of a patient with relapsing febrile nodular nonsuppurative panniculitis. J. Infect. Dis. 165 (1992) 596-597
56. Wilske B., Zöller L., Brade V., Eiffert H., Göbel U.B., Stanek G., and Pfister H.W. Qualitätsstandards in der Mikrobiologisch-infektiologischen Diagnostik: Lyme-Borreliose (2000), Urban & Fischer Verlag, München
57. Wormser G.P., Nadelman R.B., Dattwyler R.J., Dennis D.T., Shapiro E.D., Steere A.C., Rush T.J., Rahn D.W., Coyle P.K., Persing D.H., Fish D., and Luft B.J. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin. Infect. Dis. 31 Suppl. 1 (2000) 1-14
58. Wormser G.P., Ramanathan R., Nowakowski J., McKenna D., Holmgren D., Visintainer P., Dornbush R., Singh B., and Nadelman R.B. Duration of antibiotic therapy for early Lyme disease. Ann. Intern. Med. 138 (2003) 697-704
59. Xu Y., and Johnson R.C. Analysis and comparison of plasmid profiles of Borrelia burgdorferi sensu lato strains. J. Clin. Microbiol. 33 (1995) 2679-2685
60. Zore A., Ružić-Sabljić E., Maraspin V., Cimperman J., Lotric-Furlan S., Pikelj A., Jurca T., Logar M., and Strle F. Sensitivity of culture and polymerase chain reaction for the etiologic diagnosis of erythema migrans. Wien. Klin. Wochenschr. 114 (2002) 606-609